Measurement of the serum level of Elabela for the early detection of acute kidney injury in hospitalized Iraqi COVID-19 patients
DOI:
https://doi.org/10.32007/jfacmedbagdad.6431928Abstract
Background: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is caused coronavirus disease
2019 (COVID-19) affecting people worldwide. The angiotensin converting enzyme2 (ACE2) represents a
receptor of SARS-CoV-2 on the infected host cell. Apelin or its receptor agonists suppress the production of
angiotensin-converting enzyme (ACE) and angiotensin II (Ang-II) and is characterized by a protective effect
against SARS-CoV-2.
Objective: The study aims to assess the serum level of Elabela biomarker as an early detector for Acute
Kidney Injury (AKI) in patients with COVID-19.
Cases and Methods: This is a case-control study which included 45 hospitalized adult patients in multiple
centers (public hospitals) receiving COVID-19 cases in Baghdad. These cases had a positive real-time or
reverse transcription polymerase chain reaction (RT-PCR) of nasal/oropharyngeal swabs. Excluded from the
study were those with a negative PCR and comorbidities and 43 apparently healthy adult subjects as controls.
The age range of the cases and controls was (20 to 60) years
Result: There are no a statistically significant differences between the two groups in terms of age and gender
distribution. Statistically significant differences were found in terms of eGFR, S. Creatinine, D. dimer,
NEU×103
/µL, LYM×103
/µL and ELA biomarker. Significant negative correlations were found between
Elabela with D. dimer and NEU×103
/µL, and between eGFR with S. creatinine, D. Dimer, and NUT×103
/µL.
Conclusion: The Elabela biomarker can be used for the early detection of acute kidney injury in COVID-19
patients.
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2022 maha hassan Gadhi, Eman S. Saleh
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Permit others to copy and distribute the manuscript; to extract, revise, and create another derivative
works of or from the manuscript (e.g., a translation); to incorporate the manuscript into a
collective work; and to text or data mine the article, even for commercial purposes, provided that
the author(s) is/are credited; the article's modifications should not harm the author's honor or
reputation; and the article should not be altered in a way that would cause the author to lose them
reputation. The Creative Commons Attribution 4.0 International License (CC BY 4.0) has more
information.